Top Tweets for #QMSMedi
QMS Medical Completes 100% Acquisition of Saarathi Healthcare for ₹14.23 Crore - https://t.co/5O6eKi30YF
#QMSMEDI #QMSMedicalAlliedServices #StocksInNews
#Acquisition | Rs 14.225 Cr acquisition takes QMS Medical's Saarathi Healthcare stake to 100% after buying the remaining 24%.
#QMSMEDI #QMSMedical #SaarathiHealthcare #MedicalEquipment #QMSMedicalAlliedServicesShareLatestNews
CORPORATE ACTION TODAY :
NEW LISTING - #MILKYMIST EQ - Milky Mist Dairy Food Limited
CIRCUIT FILTER CHANGE :
#ALPHAGEO 20 TO 10%
#BI 20 TO 10%
#TPHQ 20 TO 10%
#ZEEMEDIA 20 TO 10%
STOCKS MOVED INTO T2T :
#ABMINTLLTD; #QMSMEDI
#QMS #QMSMedical #QMSMedi #QMSMedicalAlliedServices
QMS Medical Allied Services Q1 FY27 Concall Highlights:
👉FY27 & Future Outlook :
▫️Maintain earlier top-line guidance of ~₹220 Cr for full-year FY27 (conservative; too early to revise post-Q1; H2 typically stronger in pharma cycle)
💠Services revenue visibility ~₹90-100 Cr (PSP ~₹100-105 Cr including Saarathi; current run-rate + pipeline)
💠EBITDA margin guidance maintained at ~18% for FY27 (Q1 at 14.6%; ramp-up expected to lift full-year average)
▫️Focus areas: Scale Patient Support Programs (PSP) via deeper pharma partnerships & therapeutic expansion; expand Q-Devices + Point-of-Care offerings; leverage proprietary tech platform for scalable, data-driven patient engagement
💠Full acquisition of remaining 24% stake in Saarathi Healthcare by end-Q2FY27 to strengthen disease management & end-to-end patient journey capabilities
▫️Long-term ambition: Build comprehensive healthcare solutions platform combining medical products, patient-engagement technology & nationwide execution; confident of sustainable growth from structural shift to patient-centric care
👉Current projects and future pipeline:
▫️PSP (incl. Saarathi): Q1 revenue ~₹17.6 Cr; annual contracts (cost-plus markup); current contracts support ~₹70 Cr run-rate (17.6×4)
💠Additional negotiations underway for +₹5-7 Cr → total PSP visibility ₹100-105 Cr in FY27
💠Stickiness: 60-70% contract renewals YoY; typical 1-3 year duration with 5-12% price hikes embedded; high retention as PSPs are marketing/relationship tools (not first cost-cut targets)
▫️B2B Health Camps: 11,497 camps in Q1FY27 (~40% QoQ increase); revenue ₹6.4 Cr (corrected); complementary to PSP (screening → adherence/disease management); higher therapeutic depth (incl. GLP-1) driving value
💠Combined Services (PSP + Camps): ~₹24-25 Cr in Q1; higher margin (camps > PSP; blended 20-25% EBITDA)
▫️Q-Devices: Q1 revenue ~₹3 Cr (FY26 full-year ₹14 Cr); 17+ products currently; targeting 10-15% of overall revenue contribution in FY27
💠20-25% of product revenue in 3 years via new tech-based launches & Point-of-Care expansion
💠Pipeline: New PSP contracts under negotiation (3-6 month gestation); GLP-1 programs (4-5 already live); expansion into medium-sized pharma via camps; Point-of-Care & eGrameen for rural/semi-urban reach
👉Other notable points:
▫️Q1FY27 Segment mix shift: Services 41% (vs 24% in Q1FY26); Products 59% — driving gross-margin expansion (services mix higher)
💠Employee costs rose to ₹11.2 Cr (from ₹5.7 Cr QoQ / ₹3.2 Cr YoY) due to PSP-linked hiring (cost-plus recovered via clients); stable run-rate expected unless new contracts require scale-up
💠Main-board migration completed 18 June 2026; 76% Saarathi stake already held (full integration by Q2)
▫️Proprietary tech platform: Supports 100+ programs & 1M+ patients with real-time analytics; CDSCO license remains high entry barrier
💠Products: 900+ SKUs; Q1 product revenue ₹33 Cr (incl. Q-Devices); multi-channel (pharma/hospitals ₹24 Cr, Point-of-Care ₹9 Cr, e-commerce ₹0.16 Cr)
👉Mainboard stocks often get all the attention but some of the most compelling businesses are hiding in plain sight — on the SME Platform.
👉Smaller. Less covered, though noisy at times. Yet occasionally, genuinely exceptional.
———
👉Introducing SME Gems — a new independent series on Hidden Champions of the SME Platform :
💠 OBSC Perfection
💠 Aimtron Electronics
💠 Yash Highvoltage
💠 CFF Fluid Control
💠 DSM Fresh Foods
💠 L.T. Elevator
💠 Monolithisch India
💠 GSM Foils
👉Across Different Sectors. One common place.
🔗 https://t.co/Sto1a1qHIQ
👉Stay tuned for more insights
———
⚠️ For educational purposes only. Not investment advice. Please DYODD.
#SMEGems #SMEPlatform #HiddenChampions #SME
#SME #QMS #QMSMedical #QMSMEDI
QMS Medical Allied Services Limited Q4 & FY26 Earnings Call Highlights
👉FY27 & Future Outlook:
▫️Revenue guidance maintained at ₹216 Cr for FY27 (~25% YoY growth), fully on track with earlier indications
💠Services segment (currently 31% of revenue) targeted to double to ~₹108 Cr, powered by new patient support programs (PSP), disease management initiatives, and GLP-1 drug launches requiring high patient engagement
💠Camps revenue expected to rise to ₹18-20 Cr (from ₹13 Cr in FY26) through higher-value and varied camp formats
💠Product segment to grow at a steady 10-15%, shifting overall revenue mix toward higher-margin, stickier services business
💠EBITDA margins projected at 18-19% for FY27 (vs. ~15% in FY26), with services delivering ~25% EBITDA margin and products at 10-12%; margin expansion driven by front-loaded investments now yielding revenue
👉Current projects, signed contracts & future pipeline:
▫️Full visibility and locked-in contracts on the services side with order pipeline for FY27 doubling
💠Multiple new patient service programs already signed (total 104 different PSP + camp programs currently active across therapy areas including diabetes, hypertension, respiratory, oncology, and GLP-1 therapies)
💠Key live programs include Humrahi (Lupin) — currently engaging >3.2 lakh patients — and My Aarambh (Emcure); several additional GLP-1 and chronic-disease programs slated for launch and ramp-up
💠Saarthi Healthcare (76% stake) fully integrated; technology platform now serves >1 million patients with real-time tracking, monitoring, analytics, counseling, reminders, and outcome tracking
💠Camps pipeline: 32,380 camps successfully executed in FY26; FY27 focus on scaling higher-revenue camp variants (e.g., combination screening, per-patient models, BMD, HbA1c + retinopathy) rather than just volume
👉Other notable points:
▫️FY26 Financials: Margin compression deliberate due to front-loaded investments in people (employee cost up to ₹15.2 Cr), software development, DPDP Act compliance, and ISO certification
💠Segment mix: Products 69% (~₹119 Cr), Services 31% (~₹54 Cr, of which camps ₹13 Cr)
💠H2 FY26 revenue moderated to ~₹70-74 Cr (vs. ₹91-92 Cr in H1) due to product-side supply chain disruptions and order delays; these issues largely alleviated for FY27
💠Hiring momentum — ~850 employees already onboarded (target 1,200 for one major program); all program-specific and fully recoverable through management fees charged to pharma clients
💠Business differentiation: QMS operates as an infrastructure partner for pharma companies — handling screening camps, patient onboarding, adherence support, diagnostics, tele-interventions, and outcome monitoring — addressing high drop-off rates (patients often discontinue chronic therapy after the first month)
💠Competitive positioning: Not a traditional distributor; focus on compliant, tech-enabled PSPs gives edge over pure-play online distributors or platforms like Practo (which management clarified does not dominate structured patient support programs)
💠Scale metrics: 130+ institutional clients (including 50+ leading pharma companies), 5,000+ serviceable pin codes, 900+ SKUs, and own Q Devices brand
💠Additional: NSE main-board migration approved; investments in data protection and ISO compliance also benefit pharma partners by ensuring regulatory adherence
👉Mainboard stocks often get all the attention but some of the most compelling businesses are hiding in plain sight — on the SME Platform.
👉Smaller. Less covered, though noisy at times. Yet occasionally, genuinely exceptional.
———
👉Introducing SME Gems — a new independent series on Hidden Champions of the SME Platform :
💠 OBSC Perfection
💠 Aimtron Electronics
💠 Yash Highvoltage
💠 CFF Fluid Control
💠 DSM Fresh Foods
💠 L.T. Elevator
💠 Monolithisch India
💠 GSM Foils
👉Across Different Sectors. One common place.
🔗 https://t.co/Sto1a1qHIQ
👉Stay tuned for more insights
———
⚠️ For educational purposes only. Not investment advice. Please DYODD.
#SMEGems #SMEPlatform #HiddenChampions #SME
QMS Medi Allied Ser. 📞 Q4 & FY26 Concall Summary #QMSMEDI
🟡 MANAGEMENT PROJECTION :
For FY27, QMS targets to double service revenue to approximately 100 crores, driven by patient assistance programs, especially for GLP-1 drugs. The company anticipates an expansion in the product segment at 10% to 15% growth. Camp revenue is projected to increase to 18-20 crores. The overall revenue for FY27 is projected at around 206 crores.
🔴 Red Alert :
Margin compression in FY26 was due to significant upfront investments in people, infrastructure, and technology for upcoming service programs, leading to Q4 margin hits. Employee costs increased from 9.6 crores to 15.2 crores in FY26, driven by Saarthi integration and expansion hires for patient service programs. This frontloading of expenses impacts immediate profitability.
🟢 Green Alert :
In FY26, revenue grew 11% year-on-year to 172.9 crores, with EBITDA at 25.9 crores and PAT at 11.9 crores. The product segment contributed 69% of revenue (approx. 120 crores), while services, including camps and patient engagement, contributed 31% (approx. 50 crores), with camps contributing around 13 crores. Service segment EBITDA margins are around 25%.
🔵 Blue Alert :
QMS is strategically focusing on expanding its patient support programs (PSP) and disease management services, evidenced by increasing its stake in Saarthi Health Care to 76%. The company is investing heavily in technology and software development to ensure DPDP Act compliance and enhance its service offerings for pharmaceutical partners. This pivot aims to capture growth in the patient-centric healthcare engagement model.
🧠 Deep Insight :
The core growth driver for QMS Medi Allied Services is the strategic shift towards patient-centric services, aiming to double service revenue to 100 crores in FY27, funded by pharmaceutical companies. This is supported by significant investments in technology and a robust patient engagement platform, with current FY26 revenue at 172.9 crores and projected service segment margins of 25%. The company is leveraging its extensive network of 32,380 camps and 120 personnel to manage patient adherence and improve healthcare outcomes.
**SME News Bulletin 2025-09-24**
[Rights Issue Allotment]
#QMSMEDI - QMS Medical Allots 14,87,443 Shares in Rights Issue Board Meeting Outcome
#QMSMEDI - QMS Medical Board Meeting on Rights Issue Allotment
[Board Meeting Outcomes]
#ALPEXSOLAR - Alpex Solar Limited announces board meeting outcome on September 24, 2025
#KONTOR - Kontor Space Limited Holds Board Meeting on September 24, 2025
[New Orders/Contracts]
#SLONE - Slone Infosystems Limited Secures New Orders/Contracts
#GPECO - GP Eco Solutions India Limited Secures New Orders/Contracts
[Company Updates]
#ALLETEC - all e technologies limited holds investor meet
#ALLETEC - All E Technologies Clarifies Impact of Recent H1B Visa Fee Increase
#ALLETEC - Alletec announces brand refresh to investors
[Promotions and Appointments]
#KONTOR - Kontor Space Limited appoints Sanjeev Chhajed as CFO starting September 24, 2025
#CRAYONS - Crayons Advertising Limited appoints Ashraye Lalani as Executive Director starting August 27, 2025
[Acquisitions and Subsidiaries]
#SAROJA - Saroja Pharma Industries India Limited announces cessation of whole-time director Mr. Manish Dasharath Kamble
#SANDCODE - Sancode Technologies Ltd Acquires SanCode Semi Private Limited, Becomes Subsidiary
[Certificates and Approvals]
#MASTER - Master Components Limited receives certificate of silver maturity from TÜV SÜD Management Service GmbH
#DANISH - Danish Power Limited receives Zed Gold certificate from MSME ministry
[Product Launches]
#CHATHA - Chatha Foods Limited Launches RTE & RTC Food Range 'Unifayre' for Direct-to-Consumer Market
**SME News Bulletin 2025-02-18**
[Financial Performance]
#VOEPL - Virtuoso Optoelectronics Ltd Achieves 44% Revenue Growth in Q3 FY25, Projects 45-55% Growth for FY26
#QMSMEDI - QMS Medical Allied Services Reports 41.8% Increase in PAT in Q3FY25
#MADHUSUDAN - Madhusudan Masala Limited Reports 16.48% Increase in Q3 Revenue to Rs. 5,638 Lacs
[Business Expansion]
#SYSTANGO - Systango Expands Fresher Hiring Program, Onboarding 25 Freshers in 1st Half for AI and Data Training in 2025
#APS - Australian Premium Solar (India) Limited Awarded Tender for Off-Grid Solar Photovoltaic Water Pumping Systems in Madhya Pradesh
#QUESTLAB - Quest Laboratories Limited Acquires 44000 sqft. of Land in Pithampur, Dhar District
[Corporate Actions]
#MADHAVBAUG - Madhavbaug forfeits 16,34,400 warrants at Rs. 261 each due to non-exercise
#AFFORDABLE - Affordable Robotic & Automation Ltd. Corrects Quarterly Financial Results Submission
#SHERA - Shera Energy Clarifies Discrepancies in EGM Notice, Corrects Allottee Name and Lock-in Period
[Acquisitions and Contracts]
#EFACTOR - Efactor acquires 7.64% shares of Mis E Factor Experiences Limited
#RBMINFRA - RBM Infracon Limited Receives Work Order Worth Rs. 4,23,90,900.00 from Nayara Energy in Gujarat
#ANLON - Anlon Technology Solutions Bags Rs. 16.27 Cr Order from Cochin International Airport
#QMSMEDI #QMS Medical Allied Services Ltd #SME
Market Cap₹ 181 Cr.
Stock P/E 20.2
Promoter holding 73.7 %
10 साल आर या पार !! 0 HERO 😎🤑
#Disclaimer: It's not a buy/sell recommendation. Posts/Views are only for educational & learning.
Disclaimer
SEBI Guidelines
🚫No Direct or Indirect Buy, Sell & Hold
🚫No Tips/Advice
🚫No PMS
If anyone wants to learn without moh maya for self-reliance drop me an MSG (DM) me Remember Nothing is free 100% Paid (Without Moh maya)
♦️I'm not a SEBI Registered Research Analyst or Investment Adviser.
♦️This Twitter Account does not provide any direct or indirect buy, sell & hold recommendations
📌 DISCLAIMER:-🟥🟥
⚡️Views Only For Education Purpose. I'm Not SEBI Registered RA.
⚡️We Are Not Responsible For Any Loss.
⚡️ Some Stocks might be picked from other Analytics but will share with my view,
⚡️Derivative F&O (CE/PE) Is Very Risky Game.Takeing Any Action you are Responsible of Losses (I am not Responsible)
⚡️Please consult your financial advisor before investing.
All Research for Educational Purposes Only
⚡️⚠️ By reading this Disclaimer, I acknowledge that I am using this information at my own risk.
KEEP OBSERVING & KEEP LEARNING
✅ Follow Like ❤️ Retweet ♻️ For Max Reach!!
@primepaisa1
#Multibagger #BREAKOUTSTOCKS
#breakoutstocks #StocksToBuy #StocksInFocus
#QMS Medical Allied Services Ltd #QMSMEDI
#SME #MICROCAP
Market Cap₹ 240 Cr.
ROCE14.7 %
ROE12.1 %
Promoter holding73.7 %
Sales growth 5Years18.7 %
SME OR MICRO CAP चार्ट पे अलग ही खेल होता है, इसे समझना बच्चों के बस की नहीं बाकी सब मोह माया हैं! 🤣😍
#Disclaimer: It's not a buy/sell recommendation. Posts/Views are only for educational & learning.
Disclaimer
SEBI Guidelines
🚫No Direct or Indirect Buy, Sell & Hold
🚫No Tips/Advice
🚫No PMS
If anyone wants to learn without moh maya for self-reliance drop me an MSG (DM) me Remember Nothing is free 100% Paid (Without Moh maya)
♦️I'm not a SEBI Registered Research Analyst or Investment Adviser.
♦️This Twitter Account does not provide any direct or indirect buy, sell & hold recommendations
📌 DISCLAIMER:-🟥🟥
⚡️Views Only For Education Purpose. I'm Not SEBI Registered RA.
⚡️We Are Not Responsible For Any Loss.
⚡️ Some Stocks might be picked from other Analytics but will share with my view,
⚡️Derivative F&O (CE/PE) Is Very Risky Game.Takeing Any Action you are Responsible of Losses (I am not Responsible)
⚡️Please consult your financial advisor before investing.
All Research for Educational Purposes Only
⚡️⚠️ By reading this Disclaimer, I acknowledge that I am using this information at my own risk.
KEEP OBSERVING & KEEP LEARNING
✅ Follow Like ❤️ Retweet ♻️ For Max Reach!!
@primepaisa1
#Multibagger #BREAKOUTSTOCKS
#breakoutstocks #StocksToBuy #StocksInFocus
SME Bulletin - August, 29 2024
Part III
★ Transcript
1. QMS Medical Allied Services Ltd shared the audio recording of its Earnings Call for Q1 FY24, held on August 28, 2024. The financial results were approved on August 13, 2024. #QMSMEDI
💡📢 Like this bulletin? Repost to share the knowledge! 📢💡
SME Results Announced on 13-Aug-2024
At a Glance
🌟 QoQ Q1FY25 vs Q4FY24
#ZTECH
Revenue Down 26.73% at ₹1,624.06 lakhs
Net Profit Down 49.12% at ₹234.95 lakhs
#SOTAC
Revenue Down 4.9% at ₹2,549.65 lakhs
Net Profit Down 10.7% at ₹134.65 lakhs
#QMSMEDI
Revenue Down 5.98% at ₹3,047.60 lakhs
Net Profit Up 55.65% at ₹239.52 lakhs
#AISL
Revenue Down 0.01% at ₹5,305.76 lakhs
Net Profit Down 12.99% at ₹168.24 lakhs
-=x=-
🌟 QoQ Q1FY25 vs Q1FY24
#SUPREMEPWR
Revenue Up 0.86% at ₹2,752.51 lakhs
Net Profit Up 22.32% at ₹348.23 lakhs
QMS Medical Allied Services Limited : Intimation for Share Purchase Agreement in relation to acquisition of stake in Saarathi Healthcare Private Limited
#QMSMEDI
Last Seen Hashtags on Sotwe
cdersukakontol
Seen from Malaysia
minichat
Seen from Argentina
avcilartraveſti
Seen from Turkey
vazados novinha
Seen from Brazil
noledreaming
Seen from United States
lauma
Seen from United States
kayseribayan
Seen from Turkey
minichat()*********
Seen from Brazil
ddlg
Seen from Brazil
incesto madre e hijo
Seen from Argentina
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.3M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers